Peptides with skin condition-improving activity and their uses

Abstract

The present application relates to a peptide having skin condition-improving activity and use thereof, and provides a peptide consisting of the amino acid sequence of SEQ ID NO: 1 and a cosmetic composition for skin condition improvement including the peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an effective ingredient.

Description

[Technical Field]

[0001] This application relates to a peptide with skin condition-improving activity and its uses. [Background Technology]

[0002] Human skin undergoes constant changes, most notably the decline in skin function and visual appeal caused by aging. Aging leads to wrinkles, and representative factors contributing to wrinkle formation include exposure to ultraviolet radiation and reduced collagen biosynthesis. Skin aging can be broadly categorized into endogenous aging caused by genetic factors and extrinsic aging caused by external environmental factors such as sunlight. For extrinsic aging, it is known that it can be prevented, treated, or delayed by removing reactive oxygen species, promoting fibroblast proliferation, and stimulating collagen biosynthesis.

[0003] Collagen, a major component of the extracellular matrix, is the primary matrix protein produced in fibroblasts of the skin. It constitutes a large portion of the organic matter in the skin, tendons, bones, and teeth, with particularly high concentrations in bone and the dermis. This collagen decreases with age and due to photoaging caused by ultraviolet radiation, which is known to be closely related to wrinkle formation. Furthermore, collagen plays a crucial role in wound healing, promoting collagen synthesis in damaged epithelium, thus enabling rapid and thorough wound recovery. Additionally, it has been reported that as collagen biosynthesis is promoted, the density of the basal layer and other tissues increases, leading to a decrease in melanin concentration per unit skin density, thus potentially resulting in skin brightening effects.

[0004] Against this technological backdrop, current research is being conducted on various mechanisms to improve skin condition by promoting collagen biosynthesis, fibroblast proliferation, and enhancing activity (Korean Patent Registration No. 10-1813629), but these efforts are still not perfect. [Summary of the Invention]

[0005] [Technical Issues]

[0006] One aspect provides a peptide consisting of the amino acid sequence of SEQ ID NO: 1.

[0007] On the other hand, a cosmetic composition for improving skin condition is provided, comprising a peptide of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

[0008] Other objects and advantages of this application will become clearer in conjunction with the appended claims and drawings, as well as the detailed description below. Regarding matters not described in this specification, which can be fully understood and deduced by those skilled in the art or similar fields, their descriptions are omitted.

[0009] [Technical Solution]

[0010] The various descriptions and embodiments disclosed in this application can also be applied to various other descriptions and embodiments. That is, all combinations of the various elements disclosed in this application fall within the scope of this application. Furthermore, it cannot be determined that the scope of this application is limited to the specific descriptions set forth below.

[0011] One aspect provides a peptide consisting of the amino acid sequence of SEQ ID NO: 1.

[0012] As used in this specification, the term "peptide" can refer to a linear molecule formed by amino acid residues linked together by peptide bonds. The peptide can be prepared using chemical synthesis methods known in the art, particularly solid-phase or liquid-phase synthesis techniques (US Patent Registration No. 5,516,891). As a result of efforts to develop peptides with biologically effective activity, the inventors have identified a peptide consisting of the amino acid sequence of SEQ ID NO: 1. Here, the biologically effective activity can refer to at least one of the following properties: (a) promoting fibroblast proliferation; (b) enhancing the expression of type I collagen (Col1a1), fibronectin, or elastin as extracellular matrix constituents; and (c) enhancing the expression of silent regulatory protein-1 (SIRT-1) or aquaporin-3 (AQP3) as skin barrier factors. Therefore, the peptide can be used for skin condition improvement.

[0013] In the peptide, a protecting group may be bound to the N- or C-terminus to obtain chemical stability, enhanced pharmacological properties (half-life, absorption, potency, efficacy, etc.), altered specificity (e.g., a broad range of biological activities), and reduced antigenicity. In one embodiment, the N-terminus of the peptide may be bound to any protecting group selected from the group consisting of acetyl, fluorenylmethoxycarbonyl, formyl, palmitoyl, myristyl, stearyl, butoxycarbonyl, allyloxycarbonyl, and polyethylene glycol (PEG); and / or the C-terminus of the peptide may be bound to any protecting group selected from the group consisting of amino (-NH2), tertiary alkyl, and hydrazino (-NHNH2). Furthermore, the peptide may optionally include a targeting sequence, a tag, labeled residues, or an amino acid sequence prepared for a specific purpose of increasing half-life or peptide stability.

[0014] The peptide is artificially synthesized or non-naturally occurring or engineered. "Non-naturally occurring or engineered" refers to a state generated through artificial modification, rather than its inherent state as a naturally occurring entity. Here, artificial modification may include the artificial synthesis of an amino acid sequence by mimicking the structure of multiple amino acids, or may include the above-mentioned engineering to obtain chemical stability, enhanced pharmacological properties, altered specificity, or reduced antigenicity.

[0015] The term "stability" as used in this specification may refer not only to the in vivo stability of the peptide protected from attack by proteolytic enzymes in vivo, but also to storage stability (e.g., room temperature storage stability).

[0016] On the other hand, a cosmetic composition for improving skin condition is provided, comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

[0017] In the description of the peptide, the terms or elements that are the same as those that have been mentioned before are as described above.

[0018] The term “improvement” as used in this specification may refer to all behaviors that at least alleviate or treat parameters related to the mitigation or treatment of the condition, such as the severity of symptoms.

[0019] The term "skin condition improvement" as used in this specification may refer to the process or effect of treating, reducing, or alleviating skin damage caused by endogenous or exogenous factors of the skin. For example, it may be interpreted as improvement of wrinkles, improvement of skin elasticity, wound healing, strengthening of the skin barrier, or inhibition of skin aging, but is not limited thereto.

[0020] Here, "wrinkle improvement," "skin elasticity improvement," and "wound healing" can refer to all effects of increasing the total amount of extracellular matrix factors, including promoting collagen synthesis. Furthermore, "skin barrier strengthening" can refer to strengthening the skin's inherent functions, namely preventing the leakage of moisture and nutrients from the skin and preventing harmful substances such as bacteria or viruses from invading the skin. And "skin aging inhibition" can refer to inhibiting the decline in skin function, such as wrinkles, sagging skin, and reduced elasticity. In this case, the skin aging referred to can be photoaging, such as skin aging caused by ultraviolet radiation.

[0021] The drawback of existing functional peptides is that, even if they possess effective biological activity, they cannot be effectively delivered to target tissues or cells due to their size, or they disappear from the body quickly due to their short half-life. In contrast, a cosmetic composition according to one embodiment includes a peptide composed of 10 or fewer amino acids as an active ingredient, thus exhibiting excellent skin penetration and other properties, effectively improving skin condition when applied topically to the skin.

[0022] According to one embodiment, the peptide can promote fibroblast proliferation and enhance the synthesis of extracellular matrix building blocks and skin barrier factors. Therefore, the peptide can be used as an active ingredient in cosmetic compositions for improving skin condition.

[0023] The cosmetic composition may include, but is not limited to, a cosmetically effective amount of the peptide; and / or a cosmetically acceptable carrier.

[0024] The term "cosmetically effective amount" as used in this specification refers to an amount sufficient to achieve the skin condition-improving effect of the cosmetic composition.

[0025] The weight ratio between the peptide and the cosmetically acceptable carrier can be, for example, 500:1 to 1:500, such as 450:1 to 1:450, 400:1 to 1:400, 350:1 to 1:350, 300:1 to 1:300, 250:1 to 1:250, 200:1 to 1:200, 150:1 to 1:150, 100:1 to 1:100, 80:1 to 1:80, 60:1 to 1:60, 40:1 to 1:40, 20:1 to 1:20, 10:1 to 1:10, 8:1 to 1:8, 6:1 to 1:6, 4:1 to 1:4, or 2:1 to 1:2, but is not limited thereto.

[0026] The cosmetic composition can be prepared into any dosage form commonly prepared in the art, such as solutions, suspensions, emulsions, doughs, gels, creams, lotions, powders, soaps, surfactant-containing cleansers, oils, powder foundations, liquid foundations, wax foundations, and sprays, but is not limited thereto. For example, the cosmetic composition can be prepared into softening toners, nourishing toners, nourishing creams, massage creams, serums, eye creams, cleansing creams, cleansing foams, cleansing waters, masks, sprays, or powders.

[0027] When the dosage form of the cosmetic composition is dough, skin cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tragacanth gum, cellulose derivatives, polyethylene glycol, silicon, bentonite, silica, talc or zinc oxide may be used as carrier components.

[0028] When the dosage form of the cosmetic composition is a foundation or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, or polyamide powder may be used as a carrier component. For example, if it is a spray, it may further include accelerators such as chlorofluorocarbons, propane / butane, or dimethyl ether.

[0029] When the dosage form of the cosmetic composition is a solution or emulsion, a solvent, solubilizer or emulsifier may be used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, methyl benzoate, propylene glycol, 1,3-butylethylene glycol oil, glycerol aliphatic esters, polyethylene glycol or sorbitan fatty acid esters.

[0030] When the dosage form of the cosmetic composition is a suspension, liquid phase diluents such as water, ethanol or propylene glycol, suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitan ester and polyoxyethylene sorbitan ester, microcrystalline cellulose, methyl aluminum hydroxide, bentonite, agar or tragacanth gum, etc., can be used.

[0031] When the dosage form of the cosmetic composition is a surfactant-containing cleanser, fatty alcohol sulfates, fatty alcohol ether sulfates, sulfosuccinate monoesters, hydroxyethyl sulfonates, imidazoline derivatives, methyl taurate, sarcosinates, fatty acid amide ether sulfates, alkylamide betaine, fatty alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives, or ethoxylated glycerol fatty acid esters may be used as carrier components.

[0032] The peptides may be incorporated into nanobodies or nanoparticles to further improve skin penetration or stability. For example, the nanobodies can be prepared using lecithin as a raw material via a microfluidic apparatus and may be incorporated into lecithin particles. Any known method may be used to prepare the nanobodies. The size of the nanobodies is preferably 30 to 200 nm. If the size of the nanobodies is less than 30 nm, skin penetration may be very rapid, leading to skin side effects; if the size of the nanobodies is greater than 200 nm, they may not easily penetrate the skin, making it difficult to achieve the desired effects.

[0033] In addition to peptides and carrier components that are active ingredients, the cosmetic composition includes conventional ingredients used in cosmetic compositions, such as antioxidants, stabilizers, solubilizers, vitamins, pigments, and fragrances.

[0034] The amount of peptides included as active ingredients in the cosmetic composition may be appropriately and non-limitingly selected according to the product form, intended use, etc. For example, they may be added in an amount of 0.01 to 15% by weight of the total weight of the cosmetic composition. Furthermore, for example, the cosmetic composition may include 1.0% to 3.0% by weight, preferably 2.0% to 3.0% by weight, of peptides based on the total weight.

[0035] On the other hand, a method for improving skin condition is provided, comprising the step of applying a cosmetic composition comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient to an individual's skin; and the use of the peptide consisting of the amino acid peptide of SEQ ID NO: 1 in the preparation of a composition for improving skin condition.

[0036] In the description of the cosmetic composition, any terms or elements that are the same as those already mentioned are as described above.

[0037] As used in this specification, the term "individual" refers to an object whose skin condition needs improvement, and more specifically, to humans or non-human primates, mice, dogs, cats, horses, and mammals such as cattle.

[0038] The terms “application,” “apply,” and “coat” used in this specification are used interchangeably and can refer to at least partially localizing a composition according to an embodiment onto a desired site or distributing a composition according to an embodiment into an individual by means of application.

[0039] On the other hand, an antioxidant composition is provided, comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

[0040] In the description of the peptide, the terms or elements that are the same as those that have been mentioned before are as described above.

[0041] The antioxidant composition may be in the form of a pharmaceutical composition, a quasi-pharmaceutical composition, or a cosmetic composition. As an example, the composition may be used as a cosmetic composition for improving skin condition or as a pharmaceutical composition for improving or treating skin damage-related disease conditions.

[0042] According to one embodiment, it is shown that the peptide can restore the reduced activity of fibroblasts or keratinocytes and enhance their antioxidant efficacy. Therefore, the peptide can be used as an active ingredient in antioxidant compositions.

[0043] As an example, the antioxidant composition may be provided in the form of a pharmaceutical composition. The pharmaceutical composition may include, but is not limited to, a pharmaceutically effective amount of the peptide; and / or a pharmaceutically acceptable carrier.

[0044] The term "pharmaceuticalally effective amount" as used in this specification may refer to an amount of the pharmaceutical composition sufficient to achieve preventive or therapeutic effects against skin injury-related diseases.

[0045] Pharmaceutically acceptable carriers are those commonly used in preparation, including, but not limited to, lactose, dextran, sucrose, sorbitol, mannitol, starch, gum arabic, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylparaben, propylparaben, talc, magnesium stearate, and mineral oil. Suitable pharmaceutically acceptable carriers and formulations are detailed in Remington's Pharmaceutical Sciences (19th edition, 1995).

[0046] The weight ratio between the peptide and the pharmaceutically acceptable carrier can be, for example, 500:1 to 1:500. As an example, the weight ratio can be 450:1 to 1:450, 400:1 to 1:400, 350:1 to 1:350, 300:1 to 1:300, 250:1 to 1:250, 200:1 to 1:200, 150:1 to 1:150, 100:1 to 1:100, 80:1 to 1:80, 60:1 to 1:60, 40:1 to 1:40, 20:1 to 1:20, 10:1 to 1:10, 8:1 to 1:8, 6:1 to 1:6, 4:1 to 1:4, or 2:1 to 1:2, but is not limited thereto.

[0047] In addition to the ingredients mentioned above, the pharmaceutical composition may further include, but is not limited to, lubricants, humectants, sweeteners, flavorings, emulsifiers, suspending agents, preservatives, etc.

[0048] The pharmaceutical composition can be administered via the gastrointestinal tract or parenterally, preferably via parenteral administration. For parenteral administration, it can be administered via intramuscular injection, intravenous injection, subcutaneous injection, intraperitoneal injection, local application, percutaneous application, etc., but is not limited thereto.

[0049] The dosage of the pharmaceutical composition may be 0.0001 to 1000 μg (micrograms), 0.001 to 1000 μg, 0.01 to 1000 μg, 0.1 to 1000 μg, or 1.0 to 1000 μg per day, but is not limited thereto, and may be prescribed differently depending on factors such as formulation method, administration method, patient's age, weight, gender, symptoms, diet, administration time, route of administration, excretion rate and reaction sensitivity.

[0050] The pharmaceutical composition can be formulated in a unit volume form using pharmaceutically acceptable carriers and / or excipients according to methods readily practiced by those skilled in the art to which this invention pertains, or can be prepared by injection into multi-volume containers.

[0051] The dosage form may be a solution, suspension or emulsion in an oily or aqueous solvent, or it may be an extractant, powder, granule, tablet or capsule, and may further include powder and / or stabilizer.

[0052] On the other hand, a food composition for improving skin condition is provided, comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

[0053] In the description of the peptide, the terms or elements that are the same as those that have been mentioned before are as described above.

[0054] The content of peptides as active ingredients included in the food composition may be appropriately and non-limitingly selected according to the food form, intended use, etc., for example, they may be added at a rate of 0.01 to 15% by weight of the total food. For example, for a health beverage composition, they may be added at a rate of 0.02 to 10g, preferably 0.3 to 1g, based on 100ml.

[0055] [Beneficial Effects]

[0056] By targeting a specific peptide, it is possible to promote the proliferation of fibroblasts and enhance the synthesis of extracellular matrix constituents and skin barrier factors, thereby enabling applications in improving skin condition, including wrinkle reduction, skin elasticity improvement, wound healing, skin barrier strengthening, or skin aging inhibition.

[0057] Therefore, peptides, based on one aspect, can be used as an effective ingredient in compositions for improving skin condition. [Attached Image Description]

[0058] Figure 1 The results show the cell proliferation level confirmed by changes in cell viability after a peptide consisting of the amino acid sequence of SEQ ID NO: 1 was added to NIH3T3 cells.

[0059] Figure 2 The results show that adding a peptide consisting of the amino acid sequence of SEQ ID NO: 1 to NIH3T3 cells confirmed an increase in the expression of extracellular matrix building blocks, namely type I collagen (Col1a1), fibronectin, and elastin.

[0060] Figure 3 This demonstrates the quantitative assessment of the expression levels of extracellular matrix components after adding a peptide consisting of the amino acid sequence of SEQ ID NO: 1 to NIH3T3 cells. Figure 3 A shows the results confirming the expression level of Col1a1. Figure 3 B shows the results confirming fibronectin expression levels. Figure 3 C indicates the results confirming the level of elastin expression.

[0061] Figure 4 The results show that adding a peptide consisting of the amino acid sequence of SEQ ID NO: 1 to HaCaT cells confirmed increased expression of skin barrier factors, namely silencing regulator protein 1 (SIRT-1) and aquaporin 3 (AQP3).

[0062] Figure 5 This demonstrates the quantitative assessment of skin barrier factor expression levels after adding a peptide consisting of the amino acid sequence of SEQ ID NO: 1 to HaCaT cells. Figure 5 A shows the results confirming SIRT-1 expression levels. Figure 5 B shows the results confirming the AQP3 expression level.

[0063] Figure 6 This paper presents the results of quantitative confirmation of changes in reactive oxygen species levels due to increased ultraviolet radiation after adding a peptide consisting of the amino acid sequence of SEQ ID NO: 1 to HaCaT cells.

Detailed Implementation Methods

[0064] The present invention will now be described in more detail through embodiments. However, these embodiments are merely illustrative of the invention, and the scope of the invention is not limited to these embodiments.

[0065] Example 1: Peptide Synthesis

[0066] Peptides with the amino acid sequence SEQ ID NO: 1 listed in Table 1 were synthesized using an automated peptide synthesizer (Milligen 9050, Millipore, USA). The synthesized peptides were purified using a C18 reversed-phase high-performance liquid chromatograph (HPLC) (Waters Associates, USA). An ACQUITY UPLC BEH300 C18 column (2.1 mm × 100 mm, 1.7 μm, Waters Co., USA) was used.

[0067] Table 1

[0068]

[0069]

[0070] [Example 2: Confirmation of the effect on promoting skin cell proliferation]

[0071] This embodiment aims to confirm the effect of the peptides according to the embodiment on skin cell proliferation by evaluating changes in the survival rate of mouse fibroblasts, i.e., NIH3T3 cells.

[0072] Specifically, NIH3T3 cells were used at a rate of 1×10⁻⁶. 4Cells were seeded at a density of 96-well plates and cultured for 24 hours. The cells were then washed once with serum-free DMEM media, and a peptide consisting of the amino acid sequence of SEQ ID NO: 1 was aliquoted at 50 μM or 100 μM into 200 μL of the serum-free medium. The plates were then incubated at 37°C in a CO2 incubator for 72 hours. The culture was then washed twice with PBS, and MTT solution at 0.5 mg / ml was aliquoted into each well. After being shielded from light, the plates were incubated at 37°C in a CO2 incubator for 4 hours, and the absorbance at 540 nm was measured using a microplate reader (Molecular Devices, USA).

[0073] As a result, it was confirmed that... Figure 1 As shown, a peptide consisting of the amino acid sequence of SEQ ID NO: 1 promotes fibroblast proliferation.

[0074] [Example 3: Confirmation of wrinkle improvement and elasticity enhancement effects]

[0075] This embodiment aims to confirm the effect of a peptide according to one embodiment on improving endogenous skin aging, including wrinkle reduction and elasticity enhancement, by measuring the expression levels of type I collagen (Col1a1), fibronectin, elastin, and hyaluronic acid, which are known dermal components.

[0076] Specifically, NIH3T3 cells were used at a rate of 3 × 10⁻⁶. 5Cells were seeded at a density of 1 / well in 6-well plates and cultured for 24 hours. After washing the cells once with serum-free DMEM media, a peptide consisting of the amino acid sequence of SEQ ID NO: 1 was aliquoted into 1 mL of the medium at 10 μM, 50 μM, or 100 μM, and cultured in a CO2 incubator at 37°C for 24 hours. The culture was then washed twice with PBS, and ribonucleic acid (RNA) was isolated from the culture using easy blue (iNtRON, Cat. No: 17061, Korea). The isolated RNA was then reverse transcribed using an RT kit (Enzynomics, Cat. No: RT200, Korea) to synthesize complementary deoxyribonucleic acids (cDNA). Then, polymerase chain reaction (PCR) was performed using primers for the synthesized 1 μg cDNA and Col1a1, fibronectin, or elastin, along with a PCR kit (enzynomics, Cat. No.: P581T, Korea). In this example, the control group was the untreated group, and the group supplemented with IGF was used as the positive control group. The nucleotide sequences of the primers used in this example are shown in Table 2 below.

[0077] Table 2

[0078]

[0079] As a result, it was confirmed that... Figure 2 and 3 As shown, the peptide, composed of the amino acid sequence of SEQ ID NO: 1, increased the expression of extracellular matrix constituents, namely Colla1, fibronectin, and elastin. These results indicate that the peptide according to one embodiment contributes to the improvement of endogenous skin aging, including wrinkle reduction and increased elasticity, by increasing extracellular matrix constituents.

[0080] [Example 4: Confirmation of Skin Barrier Strengthening Effect]

[0081] This embodiment aims to confirm the effect of a peptide according to one embodiment on skin barrier strengthening by evaluating the expression levels of silencing regulatory protein 1 (SIRT-1) or aquaporin 3 (AQP3).

[0082] Specifically, HaCaT cells were prepared at a rate of 3 × 10⁻⁶. 5Cells were seeded at a density of 10 μM / well in 6-well plates and cultured for 24 hours. After washing the cells once with serum-free DMEM media, peptides consisting of the amino acid sequence of SEQ ID NO: 1 were aliquoted into 1 mL of the medium at 10 μM, 50 μM, or 100 μM, and cultured in a CO2 incubator at 37°C for 24 hours. The cultures were then washed twice with PBS, and ribonucleic acid (RNA) was isolated from the culture products using easy blue (iNtRON, Cat. No: 17061, Korea). The isolated RNA was then reverse transcribed using an RT kit (Enzynomics, Cat. No: RT200, Korea) to synthesize complementary deoxyribonucleic acids (cDNA). Then, polymerase chain reaction (PCR) was performed using primers for the synthesized 1 μg cDNA and SIRT1-1 or AQP3, along with a PCR kit (enzynomics, Cat. No.: P581T, Korea). In this example, the control group was the untreated group, and the group supplemented with EGF was used as the positive control group. The nucleotide sequences of the primers used in this example are shown in Table 3 below.

[0083] Table 3

[0084]

[0085] As a result, it was confirmed that... Figure 4 and Figure 5 As shown, the expression of SIRT-1 and AQP3, skin barrier factors, was increased by a peptide composed of the amino acid sequence of SEQ ID NO: 1. These results indicate that the peptide according to one embodiment contributes to skin barrier strengthening and anti-aging by increasing skin barrier factors.

[0086] [Example 5: Confirmation of the reduction effect of increased reactive oxygen species due to ultraviolet radiation]

[0087] This embodiment aims to confirm the effect of a peptide according to one embodiment on the antioxidant effect in damaged skin cells by evaluating changes in the level of reactive oxygen species in skin cells due to increased exposure to ultraviolet radiation.

[0088] Specifically, HaCaT cells were prepared at a rate of 5 × 10⁻⁶. 5Cells were seeded at a density of 1 / well in 6-well plates and cultured for 24 hours. Then, after washing the cells once with serum-free DMEM media, a peptide consisting of the amino acid sequence of SEQ ID NO: 1 was aliquoted into 1 mL of the medium at 50 μM or 100 μM, and the cells were incubated in a CO2 incubator at 37°C for 1 hour. The culture was then transferred to an e-tube and mixed with 1 mL of PBS for aliquoting into wells. HaCaT cells were then irradiated with UV light at 15 mJ / cm² using a UV irradiator (VILBER LOURMAT, Cat No.: 3102-BSU, France). 2 The PBS was then removed from the wells, and 900 μL of culture medium containing the peptide was added. The culture was then incubated at 37°C in a CO2 incubator for 24 hours. The culture product was then treated with 2′,7′-dichlorofluorescin diacetate (DCFH-DA), wrapped in foil, and incubated at 37°C in a CO2 incubator for 30 minutes. The cells were then washed twice with PBS and obtained using 500 μL of 1×trypsin / EDTA solution, followed by centrifugation. The centrifuged cells were washed with PBS, and fluorescence values ​​were measured using flow cytometry (FACS, BD, USA). In this example, the control group was the untreated group, the comparison group (NC) was the group irradiated with only UV light, and the group supplemented with 50 μM Trolox (Trolox) served as the positive control.

[0089] As a result, it was confirmed that... Figure 6 As shown, a peptide composed of the amino acid sequence of SEQ ID NO: 1 reduced the level of reactive oxygen species in keratinocytes increased by ultraviolet radiation. These results indicate that the peptide according to one embodiment contributes to the antioxidant effect on skin cells induced by ultraviolet radiation.

[0090] [Dosage Form Example 1: Preparation of Peptide Nanobody]

[0091] 50 mg of the peptide from Example 1 was dissolved in 500 ml of distilled water by thorough stirring. The complex solution was then mixed with 5 g of lecithin, 0.3 ml of sodium oleate, 50 ml of ethanol, and a small amount of oil phase. The mixture was adjusted with distilled water until the total volume was 1 L. The mixture was then emulsified under high pressure using a high-pressure microfluidic homogenizer to prepare peptide nanobody particles with a size of approximately 100 nm.

[0092] [Formula Example 2: Softening Toner]

[0093] A soft toner comprising a peptide according to one embodiment and having the following composition was prepared using methods known in the art.

[0094] Table 4

[0095] peptides 1.0 1,3-Butanediol 6 glycerin 4 Polyethylene glycol 1500 1 Sodium hyaluronate 1 Polysorbate 20 0.5 ethanol 8 Benzophenone-9 0.05 Preservatives, pigments Appropriate amount fragrant Appropriate amount purified water margin total 100

[0096] [Dosage Form Example 3: Nourishing Cream]

[0097] A nourishing cream comprising a peptide according to one embodiment and having the following composition was prepared using methods known in the art.

[0098] Table 5

[0099]

[0100]

[0101] [Dosage Form Example 4: Nourishing Toner]

[0102] A nourishing toner comprising a peptide according to an embodiment and having the following composition was prepared using methods known in the art.

[0103] Table 6

[0104] peptides 3.0 1,3-Butanediol 4 glycerin 4 Cetearyl alcohol 0.8 Glyceryl stearate 1 Triethanolamine 0.13 Tocopheryl acetate 0.3 Liquid paraffin 5 Squalene 3 Oil 2 Polysorbate 60 1.5 Sorbitol Sesquioleate 0.5 Carboxyvinyl polymers 1 Preservatives, pigments Appropriate amount fragrant Appropriate amount purified water margin total 100

[0105] [Dosage Form Example 5: Serum]

[0106] An essence comprising a peptide according to one embodiment and having the following composition was prepared using methods known in the art.

[0107] Table 7

[0108]

[0109]

[0110] The description of this invention is for illustrative purposes only, and those skilled in the art should understand that the invention can be readily modified into other specific forms without changing the technical concept or essential features of the invention. Therefore, the embodiments described above should be understood as exemplary in all respects, and not as limiting.

Claims

1. A peptide consisting of the amino acid sequence of SEQ ID NO:

1.

2. The peptide according to claim 1, wherein, The N-terminus of the peptide is bound to any one of the protecting groups selected from the group consisting of acetyl, fluorenylmethoxycarbonyl, formyl, palmitoyl, myristoyl, stearoyl, butoxycarbonyl, allyloxycarbonyl, and polyethylene glycol.

3. The peptide according to claim 1, wherein, The C-terminus of the peptide is bound to a protecting group selected from the group consisting of amino, tertiary alkyl, and hydrazine groups.

4. A cosmetic composition for improving skin condition, comprising a peptide as an active ingredient according to any one of claims 1 to 3.

5. The cosmetic composition according to claim 4, wherein, The peptide was prepared in the form of nanobody.

6. Use of the peptide consisting of the amino acid sequence of SEQ ID NO: 1 in the preparation of a cosmetic composition for improving skin condition, said skin condition improvement being wound healing or inhibition of skin aging.

7. The use according to claim 6, wherein, The skin aging mentioned refers to skin aging caused by ultraviolet radiation.

8. Use of a peptide consisting of the amino acid sequence of SEQ ID NO: 1 in the preparation of a cosmetic composition for wrinkle improvement.

9. Use of a peptide consisting of the amino acid sequence of SEQ ID NO: 1 in the preparation of a cosmetic composition for improving skin elasticity.

10. Use of a peptide consisting of the amino acid sequence of SEQ ID NO: 1 in the preparation of cosmetic compositions for strengthening the skin barrier.

Images